Reduced Connexin 43 expression is associated with tumor malignant behaviors and biochemical recurrence-free survival of prostate cancer.
Connexin 43, a gap junction protein, coordinates cell-to-cell communication and adhesion. Altered Connexin 43 expression associated with cancer development and progression. In this study, we assessed Connexin 43 expression for association with clinicopathological features and biochemical recurrence of prostate cancer after radical prostatectomy. Pathological specimens were collected from 243 patients who underwent radical prostatectomy and from 60 benign prostatic hyperplasia (BPH) patients to construct tissue microarrays and immunohistochemical analysis of Connexin 43 expression. Kaplan-Meier curves and multivariable Cox proportion hazard model were performed to associate Connexin 43 expression with postoperative biochemical recurrence-free survival (BFS). Connexin 43 expression was significantly reduced or lost in tumor tissues compared to that of BPHs (39.1% vs. 96.7%, P<0.001). Reduced Connexin 43 expression was associated with high levels of preoperative PSA, high Gleason score, advanced pT stage, positive surgical margin, extracapsular extension, and seminal vesicle invasion (P < 0.05, for all). Kaplan-Meier curves showed that reduced Connexin 43 expression was associated with shortened postoperative BFS (P < 0.001). Multivariate analysis showed that reduced Connexin 43 expression, high Gleason score and advanced pT stage were independent predictors for BFS of patients (P < 0.05). Connexin 43 expression was significantly reduced or lost in prostate cancer tissues, which was associated with advanced clinicopathological features and poor BFS of patients after radical prostatectomy.
Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Ning
N
Xu
Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Hui-Jun
HJ
Chen
Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Shao-Hao
SH
Chen
Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Xue-Yi
XY
Xue
Department of Pathology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Hong
H
Chen
Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Qing-Shui
QS
Zheng
Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Yong
Y
Wei
Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Xiao-Dong
XD
Li
Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Jin-Bei
JB
Huang
Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Hai
H
Cai
Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Xiong-Lin
XL
Sun
D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D018031:Connexin 43 / Q000096:biosynthesis*; D018572:Disease-Free Survival; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*
D014408:Biomarkers, Tumor; D018031:Connexin 43; C500216:GJA1 protein, human
Connexin 43; biochemical recurrence, immunohistochemistry; malignant behavior; prostate cancer